In a surprising twist, shares of Indian pharmaceutical companies surged by 4% on Thursday, even as broader markets experienced declines. This increase follows the U.S. administration’s decision to exempt pharmaceutical products from the recently announced reciprocal tariffs. The exemption proves beneficial for the pharmaceutical sector, indicating investor confidence in the industry’s ability to navigate this challenging environment. Analysts view this development positively, as Indian drugmakers stand to gain favor in international markets without the added burden of tariffs. Will this trend continue? Investors are keeping a close eye on how pharma stocks respond in the short and long term.